Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Adult T-cell leukaemia-lymphoma; HTLV-I infections
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2016 Status changed from not yet recruiting to recruiting.
- 23 Mar 2016 Last checked against ClinicalTrials.gov record.
- 18 Mar 2016 Tumor response and its duration are now evaluated along with incidence of adverse events so trial focus changed from AR to TU + AR as per ClinicalTrials.gov record.